Human Genome Sciences, Inc.

Dosing begins in phase I trial of CCR5 mAb in patients with HIV-1

Published in Law and Health Weekly, April 30th, 2005

Human Genome Sciences, Inc., (HGSI) has begun dosing patients in a phase I clinical trial to evaluate the safety, tolerability, and pharmacology of CCR5mAb004 (CCR5 mAb) in patients who are infected with HIV-1, the retrovirus that causes AIDS.

CCR5 mAb is a fully human monoclonal antibody that specifically recognizes and binds the chemokine receptor CCR5. The CCR5 receptor is known to be a key facilitator of infection with human immunodeficiency virus (HIV-1). The phase I trial of CCR5 mAb is a randomized, placebo-controlled, dose-escalation, multicenter study in HIV-1 patients who are infected with HIV-1 and are not receiving concurrent antiretroviral therapy. The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-04-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry